◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › MRK

Merck & Company Inc (MRK) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Pharmaceuticals · DATA UPDATED 2026-07-12

Merck & Company Inc (MRK) operates in the Pharmaceuticals industry and is headquartered in Rahway, United States with about 73,000 employees. Its market capitalization is roughly $324 billion. In the fiscal year ended 2025-12-31, MRK reported $64.9B in revenue and $18.3B in net income.

Merck & Co., Inc. operates as a healthcare company worldwide.

Interactive charts & full statements → Open the MRK valuation workbench →

MRK Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$65.6B	$64.9B	$64.2B	$60.1B	$59.3B	$48.7B	$41.5B	$39.1B	$42.3B	$40.1B	$39.8B	$39.5B	$42.2B	$44.0B	$47.3B	$48.0B	$46.0B	$27.4B	$23.9B	$24.2B	$22.6B
Gross Profit	$49.8B	$46.7B	$49.0B	$44.0B	$41.9B	$35.1B	$27.9B	$27.1B	$28.8B	$27.2B	$25.8B	$24.6B	$25.5B	$27.1B	$30.8B	$31.2B	$27.6B	$18.4B	$18.3B	$18.1B	$16.6B
Gross Margin %	75.9%	72.0%	76.3%	73.2%	70.6%	72.0%	67.2%	69.3%	68.1%	67.8%	64.8%	62.2%	60.3%	61.5%	65.2%	64.9%	60.0%	67.1%	76.6%	74.6%	73.5%
Operating Income (EBIT)	$18.1B	$23.5B	$20.2B	$3.0B	$18.3B	$13.2B	$5.5B	$7.9B	$8.9B	$6.8B	$5.5B	$7.5B	$6.7B	$7.7B	$9.9B	$9.0B	$3.4B	$4.0B	$6.1B	$5.6B	$3.7B
Operating Margin %	27.6%	36.2%	31.5%	4.9%	30.8%	27.1%	13.4%	20.3%	21.1%	16.9%	13.8%	19.1%	15.8%	17.4%	20.9%	18.7%	7.3%	14.7%	25.5%	23.2%	16.3%
Net Income	$8.9B	$18.3B	$17.1B	$365M	$14.5B	$13.0B	$7.1B	$9.8B	$6.2B	$2.4B	$3.9B	$4.4B	$11.9B	$4.4B	$6.2B	$6.3B	$861M	$12.9B	$7.8B	$3.3B	$4.4B
Net Margin %	13.6%	28.1%	26.7%	0.6%	24.5%	26.8%	17.0%	25.2%	14.7%	6.0%	9.8%	11.2%	28.2%	10.0%	13.1%	13.1%	1.9%	47.0%	32.7%	13.5%	19.6%
EBITDA	$18.8B	$28.3B	$25.7B	$6.9B	$21.3B	$17.9B	$10.2B	$11.4B	$14.0B	$12.0B	$10.8B	$12.4B	$24.7B	$13.3B	$16.4B	$15.5B	$9.7B	$18.3B	$11.8B	$7.6B	$6.0B
Earnings Per Share (EPS)	$3.55	$7.28	$6.74	$0.14	$5.71	$5.14	$2.78	$3.82	$2.32	$0.87	$1.41	$1.56	$4.07	$1.47	$2.01	$2.03	$0.28	$5.67	$3.64	$1.49	$2.03
Shares Outstanding (M)	2,472M	2,507M	2,541M	2,547M	2,542M	2,538M	2,541M	2,580M	2,679M	2,748M	2,787M	2,841M	2,928M	2,996M	3,076M	3,094M	3,120M	2,273M	2,143M	2,193M	2,188M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MRK Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$16.3B	$16.3B	$17.2B	$15.8B	$15.6B	$15.6B	$16.7B	$16.1B
Gross Profit	$13.3B	$11.5B	$13.0B	$12.0B	$11.7B	$11.8B	$12.6B	$12.4B
Gross Margin %	81.9%	70.5%	75.6%	75.6%	75.1%	75.5%	75.5%	76.8%
Operating Income (EBIT)	($1.9B)	$6.2B	$7.5B	$6.4B	$6.7B	$4.3B	$4.0B	$6.1B
Operating Margin %	-11.6%	37.7%	43.4%	40.2%	43.0%	27.8%	23.9%	38.0%
Net Income	($4.2B)	$3.0B	$5.8B	$4.4B	$5.1B	$3.7B	$3.2B	$5.5B
Net Margin %	-26.0%	18.1%	33.7%	28.0%	32.5%	24.0%	18.9%	33.9%
EBITDA	($2.0B)	$6.3B	$8.1B	$6.4B	$7.3B	$5.7B	$5.6B	$7.4B
Earnings Per Share (EPS)	$-1.72	$1.19	$2.32	$1.76	$2.01	$1.47	$1.24	$2.14
Shares Outstanding (M)	2,472M	2,488M	2,498M	2,513M	2,531M	2,541M	2,541M	2,544M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MRK Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$17.9B	$16.5B	$21.5B	$13.0B	$19.1B	$14.1B	$10.3B	$13.4B	$10.9B	$6.4B	$10.4B	$12.4B	$7.9B	$11.7B	$10.0B	$12.4B	$10.8B	$3.4B	$6.6B	$7.0B	$6.8B
Capital Expenditures (CapEx)	$3.8B	$4.1B	$3.4B	$3.9B	$4.4B	$4.4B	$4.7B	$3.5B	$2.6B	$1.9B	$1.6B	$1.3B	$2.3B	$1.5B	$2.0B	$1.7B	$1.7B	$1.5B	$1.3B	$1.0B	$980M
Free Cash Flow (FCF)	$14.1B	$12.4B	$18.1B	$9.1B	$14.7B	$9.7B	$5.6B	$10.0B	$8.3B	$4.6B	$8.8B	$11.1B	$5.5B	$10.1B	$8.1B	$10.7B	$9.1B	$1.9B	$5.3B	$6.0B	$5.8B
FCF Margin %	21.5%	19.0%	28.2%	15.2%	24.8%	19.8%	13.4%	25.5%	19.6%	11.4%	22.0%	28.2%	13.1%	22.9%	17.1%	22.2%	19.9%	7.0%	22.1%	24.8%	25.6%
Dividends Paid	$8.2B	$8.2B	$7.8B	$7.4B	$7.0B	$6.6B	$6.2B	$5.7B	$5.2B	$5.2B	$5.1B	$5.1B	$5.2B	$5.3B	$5.2B	$4.8B	$4.9B	$3.5B	$3.3B	$3.3B	$3.3B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MRK Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$3.9B	$2.9B	$7.8B	$3.3B	$2.5B	$3.5B	$9.3B	$5.6B
Capital Expenditures (CapEx)	$991M	$1.0B	$987M	$764M	$1.3B	$937M	$783M	$791M
Free Cash Flow (FCF)	$2.9B	$1.8B	$6.8B	$2.5B	$1.2B	$2.5B	$8.5B	$4.8B
FCF Margin %	18.0%	11.2%	39.8%	16.0%	7.5%	16.1%	51.1%	30.1%
Dividends Paid	$2.1B	$2.0B	$2.0B	$2.1B	$2.0B	$2.0B	$2.0B	$2.0B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MRK Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$128.7B	$136.9B	$117.1B	$106.7B	$109.2B	$105.7B	$91.6B	$84.4B	$82.6B	$87.9B	$95.4B	$101.7B	$98.2B	$105.6B	$106.1B	$105.1B	$105.8B	$112.3B	$47.2B	$48.4B	$44.6B
Cash & Cash Equivalents	$5.3B	$14.6B	$13.2B	$6.8B	$12.7B	$8.1B	$8.1B	$9.7B	$8.0B	$6.1B	$6.5B	$8.5B	$7.4B	$15.6B	$13.5B	$13.5B	$10.9B	$9.3B	$4.4B	$5.3B	$5.9B
Total Liabilities	$82.8B	$84.2B	$70.7B	$69.0B	$63.1B	$67.4B	$66.2B	$58.4B	$55.8B	$53.3B	$55.1B	$56.9B	$49.4B	$53.3B	$50.7B	$48.2B	$49.0B	$50.8B	$26.0B	$27.8B	$24.6B
Total Debt (Short + Long-Term)	$49.1B	$49.6B	$37.4B	$35.3B	$31.0B	$33.4B	$32.1B	$26.3B	$25.1B	$24.4B	$24.8B	$26.5B	$21.4B	$25.1B	$20.6B	$17.5B	$17.9B	$17.5B	$6.2B	$5.7B	$6.8B
Total Shareholders' Equity	$45.9B	$52.6B	$46.3B	$37.6B	$46.0B	$38.2B	$25.3B	$25.9B	$26.7B	$34.3B	$40.1B	$44.7B	$48.6B	$49.8B	$53.0B	$54.5B	$54.4B	$59.1B	$18.8B	$18.2B	$17.6B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MRK viewer.

Other Companies in Pharmaceuticals

LLY · Lilly (Eli) — $1.07 trillion
JNJ · Johnson & Johnson — $635 billion
PFE · Pfizer — $140 billion
BMY · Bristol Myers Squibb — $127 billion
ZTS · Zoetis — $32 billion
VTRS · Viatris — $20 billion

← MRDN All stocks MRKR →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.